

Sickle Cell Disease

Measure 10: Anticipatory Guidance Regarding Hydroxyurea Treatment for Children with Sickle Cell Disease

Description

The percentage of children identified as having Sickle Cell Anemia who received anticipatory guidance regarding the risks and benefits of treatment with hydroxyurea as part of outpatient care during the measurement year. A higher proportion indicates better performance as reflected by appropriate guidance.

Calculation

This measure requires medical record data and is calculated as follows:

The percentage of eligible children who received anticipatory guidance regarding the risks and benefits of treatment with hydroxyurea (numerator divided by denominator).

Definitions

Intake period	January 1 through December 31 of the measurement year.
Anticipatory guidance	Any written or face-to-face verbal communication regarding the risks and benefits of treatment with hydroxyurea as part of outpatient care with patient, parent, or family member.
Outpatient care	A Health Maintenance Exam (HME) or an Evaluation and Management (E&M) visit with primary care provider or a specialist (see Table 10-A).

Table 10-A: Codes to Identify Ambulatory or Preventive Care Visits

Description	CPT	HCPCS	ICD-9-CM Diagnosis
Office or other outpatient services	99201-99205, 99211-99215, 99241-99245		
Preventive medicine	99381-99385, 99391-99395, 99401-99404, 99411-99412, 99420, 99429	G0438, G0439	
General medical examination			V20.2, V70.0, V70.3, V70.5, V70.6, V70.8, V70.9

Eligible Population

The determination of eligible population for this measure requires medical record data.

Ages Younger than eighteen years of age during measurement year

Event/Diagnosis Diagnosed with Sickle Cell Anemia as documented in the medical record (see Table 10-B).

NOTE: See exclusions noted below; there are several sickle cell variants that may be recorded under the 282.49 ICD-9 code that do not qualify for inclusion (see Table 10-C). Medical records for cases with ICD-9 code 282.49 should not be reviewed unless a diagnosis of Hb beta zero-thalassemia can be confirmed.

Table 10-B: Codes to Identify Sickle Cell Anemia

Condition Name	Hemoglobin Screening Result	ICD-9 Code(s)
Hb beta zero-thalassemia	Hb F only	282.49
Hb SS-disease (sickle cell anemia)	Hb F,S	282.6, 282.61, 282.62

Specification

Denominator The eligible population for the denominator is the number of children younger than 18 years of age with SCA who received outpatient care during the measurement year.

Numerator The eligible population for the numerator is the number of children younger than 18 years of age with SCA who received anticipatory guidance regarding the risks and benefits of treatment with hydroxyurea as part of outpatient care during the measurement year.

Documentation in medical record must include, at a minimum, a note containing the date on which verbal or written anticipatory guidance was provided.

Exclusions

- Inpatient stays, emergency department visits, urgent care visits.
- Children with diagnosis in the sampled medical record indicating one of the sickle cell disease variants listed in Table 10-C should not be included in the eligible population *unless* there is also a diagnosis for a sickle cell variant listed in Table 10-B.

Table 10-C: Excluded Sickle Cell Disease Diagnosis Codes

Condition Name	Hemoglobin Screening Result	ICD-9 Code(s)
Hb S beta-thalassemia	Hb F,S,A	282.41, 282.42
Hb C-disease	Hb F,C	282.7
Hb SC-disease	Hb F,S,C	282.63, 282.64
Hb SD-disease	Hb F,S,D	282.68, 282.69
Hb SE-disease	Hb F,S,E	282.68, 282.69
Hb C beta-thalassemia	Hb F,C,A	282.49
Hb D beta-thalassemia	Hb F,D,A	282.49
Hb E beta-thalassemia	Hb F,E,A	282.49
Hb E-disease	Hb F,E	282.7
Hb H-disease	Hb F,H	282.49
Hb C-carrier	Hb F,A,C	282.7
Hb D-carrier	Hb F,A,D	282.7
Hb E-carrier	Hb F,A,E	282.7
Hb S (sickle)-carrier	Hb F,A,S	282.5

